Insider Transactions in Q1 2025 at Zentalis Pharmaceuticals, Inc. (ZNTL)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2025
|
Ingmar Bruns Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+35.32%
|
$40,000
$2.28 P/Share
|
|
Feb 03
2025
|
Julia Marie Eastland CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
59,388
+40.32%
|
-
|
|
Feb 03
2025
|
Ingmar Bruns Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,629
+50.0%
|
-
|
|
Feb 03
2025
|
Andrea Paul Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,230
-1.22%
|
$13,230
$1.71 P/Share
|
|
Feb 03
2025
|
Andrea Paul Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
934,041
+46.28%
|
-
|
|
Feb 03
2025
|
Mark Lackner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,368
-2.73%
|
$14,368
$1.71 P/Share
|
|
Feb 03
2025
|
Mark Lackner Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
335,907
+38.92%
|
-
|
|
Feb 03
2025
|
Vincent Vultaggio PAO and Interim PFO |
SELL
Open market or private sale
|
Direct |
2,615
-1.36%
|
$2,615
$1.71 P/Share
|
|
Feb 03
2025
|
Vincent Vultaggio PAO and Interim PFO |
BUY
Grant, award, or other acquisition
|
Direct |
158,586
+45.18%
|
-
|
|
Jan 31
2025
|
Jan Skvarka Director |
BUY
Open market or private purchase
|
Direct |
60,000
+28.63%
|
$60,000
$1.72 P/Share
|
|
Jan 31
2025
|
Luke Nathaniel Walker Director |
BUY
Open market or private purchase
|
Direct |
14,200
+14.08%
|
$14,200
$1.76 P/Share
|
|
Jan 31
2025
|
Julia Marie Eastland CEO & President |
BUY
Open market or private purchase
|
Direct |
28,500
+50.0%
|
$28,500
$1.73 P/Share
|
|
Jan 02
2025
|
Mark Lackner Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,411
-2.25%
|
$13,233
$3.12 P/Share
|